SCHEDULE 13G/A: BlackRock Discloses Reduced Stake in Soleno Therapeutics Below 5%
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting its beneficial ownership in Soleno Therapeutics Inc. has decreased to 4.7% as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,009,790 shares of Soleno Therapeutics Inc. common stock as of December 31, 2024.
- This aggregate amount represents 4.7% of Soleno Therapeutics Inc.'s common stock class.
- BlackRock holds sole voting power over 1,980,534 shares and sole dispositive power over 2,009,790 shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change in their previously reported beneficial ownership.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing reporting a change in beneficial ownership. While a decrease in a significant institutional stake could be interpreted in various ways, the filing itself is neutral in tone and provides no qualitative assessment of the issuer or the investment.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Soleno Therapeutics Inc.'s future performance or BlackRock's future investment intentions beyond the current beneficial ownership report.
Industry Context
This Schedule 13G filing is a standard regulatory disclosure required when an institutional investor's beneficial ownership of a company's stock changes, particularly when it crosses certain thresholds. BlackRock, as a major asset manager, frequently files such reports to update its holdings. The reduction of its stake below 5% means BlackRock is no longer required to file a Schedule 13D, which is reserved for investors seeking to influence or control the issuer, and will continue to file 13G amendments for material changes.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Regulatory Compliance Filing | BlackRock, Inc. filed an amended Schedule 13G to comply with SEC beneficial ownership reporting requirements, indicating its stake in Soleno Therapeutics Inc. is now below 5%. | 2024-12-31 | Ensures transparency of significant institutional holdings, providing public insight into large investor positions. |
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, appointing new attorneys-in-fact for executing regulatory filings, revoking a previous power of attorney dated April 30, 2023. | 2025-01-21 | Streamlines internal processes for regulatory compliance and ensures proper authorization for SEC filings. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's reduced stake, which may influence investor sentiment or trading decisions.
- Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership, ensuring market transparency.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney that was revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2024-12-31 | Date of event which required the filing of this statement (reporting period end date for beneficial ownership). |
| 2025-02-05 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
BlackRock, Soleno Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.